MONITORING OF RECURRENCE IN PATIENTS RADICALLY OPERATED FOR PANCREATIC CANCER

Authors

  • S. BARBU University of Medicine and Pharmacy”Iuliu Hatieganu”, Cluj-Napoca, Romania
  • I. HUTANU Regional Institute of Oncology, Iasi
  • Å. ANDRÉN-SANDBERG Karolinska University Hospital, SE-141 86 Stockholm, Sweden
  • R.P. SOROCEANU University of Medicine and Pharmacy "Grigore T. Popa"- Iasi
  • D. TIMOFTE University of Medicine and Pharmacy "Grigore T. Popa"- Iasi

Abstract

Pancreatic cancer is a diagnosis that carries a poor prognosis. It is the fourth leading cause of cancer death in Europe and the United States, despite advances in operative technique and postoperative management. Furthermore, there is no consensus on the optimal follow-up schedule of patients after surgery for pancreatic cancer, all recommendations on surveillance being based on low level evidence or no evidence and the leading societies propose different guidelines. As a consequence, follow-up strategies may differ between hospitals depending on preference of physicians. The vast majority of patients develop recurrence within 2 years after surgery, suggesting the necessity of a more intensive follow-up the first 2 years after surgery. It usually occurs after surgery as migratory metastases along major upper abdominal arteries and veins to the liver or peritoneum (70%) and less commonly as loco regional disease as masses closely applied to the surgical margins in the neck or body of the pancreas (30%). Currently, there are no effective means to prevent pancreatic cancer recurrence, despite the fact that it is responsible for the majority of postoperative deaths.

Author Biographies

  • S. BARBU, University of Medicine and Pharmacy”Iuliu Hatieganu”, Cluj-Napoca, Romania

    The 4th Surgery Department

  • Å. ANDRÉN-SANDBERG, Karolinska University Hospital, SE-141 86 Stockholm, Sweden

    Department of Gastroentoenterological Surgery

  • R.P. SOROCEANU, University of Medicine and Pharmacy "Grigore T. Popa"- Iasi

    Faculty of Medicine
    Department of Surgery

  • D. TIMOFTE, University of Medicine and Pharmacy "Grigore T. Popa"- Iasi

    Faculty of Medicine
    Department of Surgery

References

1. Hishinuma S et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006; 10(4): 511-518.
2. Tamm EP et al. Diagnosis, staging, and surveillance of pancreatic cancer. Am J Roentgenol 2003; 180(5): 1311-1323.
3. Niedergethmann M et al. High expression of vascular endothelial growth factor predicts early recur-rence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25(2): 122-129.
4. Sperti C, Pasquali C, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 2010 Jan; 14(1): 131-40.
5. Moldovanu R, Grecu F, Târcoveanu E et al. Duodenopancreatectomia cefalică în cancerul de cap de pancreas - considerații asupra 54 cazuri. Rev Med Chir Soc Med Nat 2007; 3(2): 17-21.
6. Griffin JF, Smalley SR , Jewell W et al. Patterns of failure after curative resection of pancreatic carci-noma. Cancer 1990; 66: 56–61.
7. Kayahara M, Nagakawa T, Ueno K et al. An evaluation of radical resection for pancreatic based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993; 72: 2118–2123.
8. Kazuaki S, Sakamoto Y, Sano T, Kosuge T. The Role of Paraaortic Lymph Node Involvement on Early Recurrence and Survival after Macroscopic Curative Resection with Extended Lymphadenectomy for Pancreatic Carcinoma. J Am Coll Surg 2006; 203(3): 345-352.
9. Hannan EL, O’Donnell JF, Kilburn H et al. Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. JAMA 1989; 262(4): 503-510.
10. Steiner CA, Bass EB, Talamini MA et al. Surgical rates and operative mortality for open and laparo-scopic cholecystectomy in Maryland. N Engl J Med 1994; 330(6): 403-408.
11. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med 1979; 301(25): 1364-1369.
12. Lupascu C, Ursulescu C, Danila N et al. Early Retropancreatic Lamina Dissection During Pancreati-coduodenectomy: How, When and Why?. Rev Med Chir Soc Med Nat 2013; 117(1): 137-142.
13. Wade TP, El-Ghazzawy EG, Virgo KS, Johnson FE. The Whipple resection for cancer in U.S. De-partment of Veterans Affairs hospitals. Ann Surg 1995; 221(3): 241-248.
14. Sosa JA, Bowmna HM, Gordon TA et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998; 228(3): 429–438.
15. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222: 638-645.
16. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. Brit J Surg 2004; 91(11): 1410-1427.
17. Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005; 242: 540-544.
18. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001; 26: 254 –259.
19. Yutaka T, Toshio N, Masaru K et al. Clinical Significance Of Fluorine-18-2-Fluoro-Deoxy-D-Glucose Positron Emission Tomography In The Detection Of Recurrent Pancreatic Cancer. Pancreas 2005; 31(1): 2-3.
20. Inoue K, Kawano T, Shima K, Suzuki TK, Tobe T, Yajima H. Relationship between development of fibrosis and hemodynamic changes of the pancreas in dogs. Gastroenterol 1981; 81: 37-47.
21. Sarles H. Chronic pancreatitis and diabetes. Baillieres Clin Endocrinol Metab 1992; 6: 745-775.
22. Longnecker DS. Pathology and pathogenesis of diseases of the pancreas. Am J Pathol 1982; 107: 103-121.
23. Tajima Y, Matsuzaki S, Furui J, Isomoto I, Hakayashi K, Kanematsu T. Use of the time-signal intensity curve from dynamic magnetic resonance imaging to evaluate remnant pancreatic fibrosis after pancreaticojejunostomy in patients undergoing pancreaticoduodenectomy. Brit J Surg 2004; 91(5): 595-600.
24. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic Adenocar-cinoma. Ann Surg Oncol 2004; 11: 644-649.
25. Brockhaus M, Wysocka M, Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Normal salivary mucin contains the gastrointestinal cancer associated antigen detected by monoclonal antibody CA 19-9 in the serum mucin of patients. Vox Sang 1985; 48: 34–38.
26. Kalthoff H, Kreiker C, Schmiegel WH, Greten H, Thiele HG. Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res 1986; 46: 3605–3607.
27. Glenn J, Steinberg WM, Kurtzman SH, et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462–468.
28. Montgomery RC, Hoffman JP, Riley LB, et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997; 4: 551–556.
29. Kang CM, Kim JY, Choi GH et al. The Use of Adjusted Preoperative CA 19-9 to Predict the Recur-rence of Resectable Pancreatic Cancer. J Surg Research 2007; 140: 31-35.
30. Miyazaki M, Yoshitomi H, Shimizu H et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: Is it worthwhile?. Surgery 2014; 155: 58-66.
31. Sunagozaka H, Yamashita T, Kagaya T, Kato Y, Kaneko S. A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemo-therapy resulting progressive disease. Gan To Kagaku Ryoho 2006; 33(6): 829-832.
32. Kyriazanos ID, Tsoukalos GG, Papageorgiou G, Verigos KE, Miliadis L, Stoidis CN. Local recurrence of pancreatic cancer after primary surgical intervention: How to deal with this devastating scenario?. Surg Oncol 2011; 20(4): 133-142.

Additional Files

Published

2015-06-30

Issue

Vol. 119 No. 2 (2015): The Medical-Surgical Journal

Section

SURGERY

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form